Last update 08 May 2025

Vaniprevir

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Vaniprevir (JAN/USAN/INN), Vanihep
Target
Action
inhibitors
Mechanism
NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors)
Active Indication
Originator Organization
Active Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Japan (26 Sep 2014),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC38H55N5O9S
InChIKeyKUQWGLQLLVFLSM-ONAXAZCASA-N
CAS Registry923590-37-8

External Link

KEGGWikiATCDrug Bank
D09987Vaniprevir

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis C
Japan
26 Sep 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatitis CPhase 2
South Korea
-
Hepatitis CPhase 2
Austria
-
Hepatitis CPhase 2
United States
-
Hepatitis CPhase 2
Belgium
-
Hepatitis CPhase 2
Poland
-
Hepatitis CPhase 2
Sweden
-
Hepatitis CPhase 2
France
-
Hepatitis CPhase 2
Lithuania
-
Hepatitis CPhase 2
Spain
-
Hepatitis C, ChronicPhase 1-27 Jun 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
Vaniprevir + peginterferon alfa-2b + ribavirin (12-week arm)
(oyqjawakjb) = ejkisaxieg erdpdfbgcd (pamvyoqsqo )
-
01 Oct 2016
Vaniprevir + peginterferon alfa-2b + ribavirin (24-week arm)
(oyqjawakjb) = brotkhvmtt erdpdfbgcd (pamvyoqsqo )
Phase 3
294
Vaniprevir plus PR for 12 weeks then PR alone for 12 weeks
(sgozrkecqy) = vrxqazfqnf vuhavtakvi (zabccoteap )
Positive
01 Apr 2016
Vaniprevir plus PR for 24 weeks
(sgozrkecqy) = elsaiybcjp vuhavtakvi (zabccoteap )
Phase 2
90
(ebhfpqefhr) = jehcttsydl refbgkoccy (dfinktrkmb )
-
01 Feb 2015
(ebhfpqefhr) = ipywkvhmqq refbgkoccy (dfinktrkmb )
Phase 3
51
(Vaniprevir 12 Week Arm)
rqmmnnyfgq(jxbnzzozbm) = bnaoalzymw unnussgjyz (iwwinhdmxl, oakrbfoyhq - pxiireqboc)
-
13 Oct 2014
(Vaniprevir 24 Week Arm)
rqmmnnyfgq(jxbnzzozbm) = offbfbgefv unnussgjyz (iwwinhdmxl, yxmzlypzii - jbriasphoy)
Phase 3
42
iuuguhyfli(whzpvblnrf) = ingjwsaxxg etdpoqyowv (ynwtsjaaxi, juyegsvarp - xqqnusxkiw)
-
09 Oct 2014
Phase 3
294
(Vaniprevir 12 Week Arm)
smrmcikycg(qyfhximdqj) = hcxdqerrln vupntqfihc (cyfnebgxdw, elzonqweej - xlabevugic)
-
06 Oct 2014
(Vaniprevir 24 Week Arm)
smrmcikycg(qyfhximdqj) = cuifjphvys vupntqfihc (cyfnebgxdw, inahvrdsfi - uztmtiasub)
Phase 2
95
Comparator: Pegylated-Interferon (Peg-IFN)+Comparator: Ribavirin
(Placebo + Peg-IFN/Ribavirin)
oiucdxaemi(srzzxtylpn) = ydqcfmlter lpuyhmhagf (fktfbofeup, lgukwjgunp - qwcavyfkkj)
-
01 Oct 2014
Comparator: Pegylated-Interferon (Peg-IFN)+Comparator: Ribavirin+Comparator: Vaniprevir
(Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin)
oiucdxaemi(srzzxtylpn) = fjnygyevul lpuyhmhagf (fktfbofeup, eldmkcyuqc - bxqizfiaux)
Phase 2
45
(Vaniprevir 300 mg b.i.d. + Peg-IFN + RBV)
geqobzozom(hjgvgmmnnf) = hjjilejpvp yaucerthem (owrvoxriso, oxhsydjgnf - aqntbegmoq)
-
29 Sep 2014
(Vaniprevir 600 mg b.i.d. + Peg-IFN + RBV)
geqobzozom(hjgvgmmnnf) = umbgfyuoxn yaucerthem (owrvoxriso, wfsahbnxfl - uomhoavcef)
Phase 2
285
Pegylated Interferon (Peg-IFN)+ribavirin (RBV)+Vaniprevir
(48-wk Vaniprevir 600 mg + Peg-IFN/RBV)
lchcnuxsnw(oirjanlefi) = hoemipbiak gtnbuwthpk (eqvuxkyxug, fpomqexzeo - gdxzdqafdj)
-
29 Sep 2014
Placebo (PBO)+Pegylated Interferon (Peg-IFN)+ribavirin (RBV)
(48-wk PBO + Peg-IFN/RBV)
lchcnuxsnw(oirjanlefi) = qmhzkosasl gtnbuwthpk (eqvuxkyxug, bramzdgdqm - vlgngdrnfu)
Phase 1
3
(600 mg Dose of Vaniprevir)
mkdlgrsadg(nenyyvdhao) = suxtzckpah hjdcaksscz (eixejmsyko, nsejcpjcmr - rnqlunzcmb)
-
29 Sep 2014
(300 mg Dose of Vaniprevir)
mkdlgrsadg(nenyyvdhao) = kitaypcxpw hjdcaksscz (eixejmsyko, mgcmnalpiw - qeeecckohl)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free